SEARCH

SEARCH BY CITATION

References

  • 1
    Thom T , Haase N , Rosamond W , Howard VJ , Rumsfeld J , Manolio T , Zheng ZJ , Flegal K , O’Donnell C , Kittner S , Lloyd-Jones D , Goff DC Jr , Hong Y , Adams R , Friday G , Furie K , Gorelick P , Kissela B , Marler J , Meigs J , et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Circulation 2006 ; 113 : e85151 .
  • 2
    Gustafsson D . Oral direct thrombin inhibitors in clinical development . J Intern Med 2003 ; 254 : 32234 .
  • 3
    Leadley RJ Jr . Coagulation factor Xa inhibition: biological background and rationale . Curr Top Med Chem 2001 ; 1 : 1519 .
  • 4
    Wong PC , Crain EJ , Watson CA , Zaspel AM , Wright MR , Lam PY , Pinto DJP , Wexler RR , Knabb RM . Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits . J Pharmacol Exp Ther 2002 ; 303 : 9931000 .
  • 5
    Quan ML , Wexler RR . The design and synthesis of noncovalent factor Xa inhibitors . Curr Top Med Chem 2001 ; 1 : 13749 .
  • 6
    Wong PC , Pinto DJ , Knabb RM . Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent . Cardiovasc Drug Rev 2002 ; 20 : 13752 .
  • 7
    Pinto DJ , Orwat MJ , Koch S , Rossi KA , Alexander RS , Smallwood A , Wong PC , Rendina AR , Luettgen JM , Knabb RM , He K , Xin B , Wexler RR , Lam PY . Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa . J Med Chem 2007 ; 50 : 533956 .
  • 8
    He K , He B , Grace JE , Xin B , Zhang D , Pinto DJ , Luettgen JM , Knabb RM , Lam PYS , Wexler R , Humphrey WG , Shyu W-C , Grossman SJ . Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective factor Xa inhibitor . Blood 2006 ; 108 : 273a ( Abstract# 910 ).
  • 9
    Frost C , Yu Z , Nepal S , Mosqueda-Garcia R , Shenker A . Apixaban, an oral direct, factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects . J Thromb Haemost 2007 ; 5 Suppl. 2 : PM665 .
  • 10
    Lassen MR , Davidson BL , Gallus A , Pineo G , Ansell J , Deitchman D . The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement . J Thromb Haemost 2007 ; 5 : 236875 .
  • 11
    Büller HR . A dose finding study of the oral direct factor Xa inhibitor Apixaban in the treatment of patients with acute symptomatic deep-vein thrombosis – on behalf of the Botticelli investigators . J Thromb Haemost 2007 ; 5 Suppl. 2 : OS003 .
  • 12
    Miletich JP , Broze GJ Jr , Majerus PW . Purification of human coagulation factors II, IX, and X using sulfated dextran beads . Methods Enzymol 1981 ; 80 : 2218 .
  • 13
    Mousa SA , Wityak J . Orally active isoxazoline GPIIb/IIIa antagonists . Cardiovasc Drug Rev 1998 ; 16 : 4861 .
  • 14
    Sato K , Taniuchi Y , Kawasaki T , Hirayama F , Koshio H , Matsumoto Y . Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats . Eur J Pharmacol 1998 ; 347 : 2316 .
  • 15
    Wong PC , Crain EJ , Knabb RM , Meade RP , Quan ML , Watson CA , Wexler RR , Wright MR , Slee AM . Nonpeptide factor Xa inhibitors: II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis . J Pharmacol Exp Ther 2002 ; 295 : 21218 .
  • 16
    Wong PC , Quan ML , Crain EJ , Watson CA , Wexler RR , Knabb RM . Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics . J Pharmacol Exp Ther 2000 ; 292 : 3517 .
  • 17
    Hollenbach S , Sinha U , Lin P-H , Needham K , Frey L , Hancock T , Wong A , Wolf D . A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis . Thromb Haemost 1994 ; 71 : 35762 .
  • 18
    Krishnaswamy S . Exosite-driven substrate specificity and function in coagulation . J Thromb Haemost 2005 ; 3 : 5467 .
  • 19
    Luettgen JM , Wang Z , Seiffert DA , Rendina AR , Knabb RM , Ogletree ML . Inhibition of measured thrombin generation in human plasma by apixaban: a predictive mathematical model based on experimentally determined rate constants . J Thromb Haemost 2007 ; 5 ( Suppl. 2 ): PT633 .
  • 20
    Hara T , Yokoyama A , Morishima Y , Kunitada S . Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor . Thromb Res 1995 ; 80 : 99104 .
  • 21
    Perzborn E , Strassburger J , Wilmen A , Pohlmann J , Roehrig S , Schlemmer KH , Straub A . In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct factor Xa inhibitor . J Thromb Haemost 2005 ; 3 : 51421 .
  • 22
    Peters RF , Lees CM , Mitchell KA , Tweed MF , Talbot MD , Wallis RB . The characterization of thrombus development in an improved model of arterio-venous thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP  39393), heparin, and iloprost . Thromb Haemost 1991 ; 65 : 26874 .
  • 23
    Fukuda T , Matsumoto C , Honda Y , Sugiyama N , Morishima Y , Shibano T . Antithrombotic properties of DU-176b, a novel, potent and orally active direct factor Xa inhibitor in rat models of arterial and venous thrombosis: comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor . Blood 2004 ; 104 : 11 ( Abstract# 1852 ).
  • 24
    Brufatto N , Ward A , Nesheim ME . Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex . J Thromb Haemost 2003 ; 1 : 125863 .
  • 25
    Gerotziafas GT , Elalamy I , Depasse F , Perzborn E , Samama MM . In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban . J Thromb Haemost 2007 ; 5 : 8868 .
  • 26
    Walenga JM , Jeske WP , Samama MM , Frapaise FX , Bick RL , Fareed J . Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent . Expert Opin Investig Drugs 2002 ; 11 : 397407 .